Potential neurodegenerative disease therapies may show efficacy in preclinical research, but too often cannot be replicated or fail to translate from in vivo platforms to clinical results. This makes drug development slower, more expensive, and financially risky.
Improving the design of efficacy studies could solve this problem. We need a central resource for sharing preclinical efficacy data and best practices in this emerging field.
The Alzheimer’s Disease Preclinical Efficacy Database (AlzPED) is a web-based knowledge portal for housing, sharing, and mining preclinical efficacy data. Each study is curated by two experts for potential conflicts of interest, AD animal models, targets, outcomes, and – most importantly – the rigor of the study.
In this webinar, we join Dr. Lorenzo Refolo, Director for Alzheimer’s Disease Drug Discovery and Development at the National Institute on Aging (NIA), to learn how AlzPED can promote the reproducibility and translatability of neuroscience research.
Watch this webinar to:
Dr. Refolo is the Director for Alzheimer’s Disease Drug Discovery and Development at the NIA. He received his PhD in Molecular Genetics from the Rutgers University School of Medicine, with postdoctoral training at the Laboratory of Neurobiology at Rockefeller University and the Department of Psychiatry at Mount Sinai School of Medicine.
© 2021 Taconic Biosciences, Inc. All rights reserved.